Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Go back to Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials| Merck & Co. (NYSE: MRK) | Delayed: 140.53 -1.29 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $141.82 | 52 Week High | $65.46 | |||
| Open | $140.00 | 52 Week Low | $47.97 | |||
| Day High | $142.40 | P/E | 95.60 | |||
| Day Low | $139.21 | EPS | $1.47 | |||
| Volume | 4,115,328 | |||||



